Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IB, Open-Label Study Evaluating the Safety and Pharmacokinetics of Venetoclax (GDC-0199, ABT-199) in Combination With Bendamustine+Rituximab (BR) or Bendamustine+Obinutuzumab (BG) in Patients With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia

NCT01671904 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT01671904
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01671904 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IB, Open-Label Study Evaluating the Safety and Pharmacokinetics of Venetoclax (GDC-0199, ABT-199) in Combination With Bendamustine+Rituximab (BR) or Bendamustine+Obinutuzumab (BG) in Patients With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 13, 2014
Completion date
August 11, 2020
Enrollment
84 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia